T2 Biosystems Inc (TTOO)

[Noitall1]

Ttoo
Of course this will affect the sales. It will have devastating consequences. The result is that the sepsis detection market is surprisingly tiny and highly unprofitable. In 2022, T2 Biosystems generated only $11.3 million in product revenues, spending roughly $21.1 million in direct costs alone. (R&D and overheads would add another $56 million to that figure). Revenues are also expected to fall. On Monday, the company’s management lowered their 2023 guidance from a $12 million sales midpoint to $10 million.
Butt.
A valley full of sheep bring a lot of temporary volume which throw off the bears!